- Primary research
- Open Access
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells
© Yang et al.; licensee BioMed Central. 2014
- Received: 5 July 2014
- Accepted: 14 October 2014
- Published: 12 November 2014
Suberoyl bis-hydroxamic acid (SBHA) is a histone deacetylase (HDAC) inhibitor and exerts anti-growth effects in several malignancies including breast cancer. Proteasome inhibitors such as Bortezomib and MG-132 constitute novel anticancer agents. In this study, we investigated the synergistic antitumour activity of SBHA in combination with proteasome inhibitors.
MCF-7 and MDA-MB-231 breast cancer cells were treated with SBHA, Bortezomib, and MG-132 alone or in combination for 72 h. Cell proliferation, colony formation, apoptosis and gene expression changes were examined.
SBHA, Bortezomib, and MG-132 alone significantly inhibited the proliferation and colony formation and induced apoptosis in MCF-7 and MDA-MB-231 cells. Combined treatment showed a good synergistic antitumour effect against breast cancer cells. The p53 protein level was significantly elevated by combined treatment with SBHA and proteasome inhibitors. Moreover, combined treatment increased the expression of Bax, Bcl-xS, and Bak and decreased the expression of Bcl-2. Combination of SBHA with proteasome inhibitors causes synergistic anticancer effects on breast cancer cells. The potential molecular mechanism may involve induction of p53 and modulation of the Bcl-2 family proteins.
These findings warrant further investigation of the therapeutic benefits of combination of SBHA with proteasome inhibitors in breast cancer.
- Anticancer therapy
- Bcl-2 family
- Histone deacetylase
- Proteasome inhibition
Breast cancer is one of the most common malignant diseases affecting females worldwide, with more than 450,000 deaths each year . The current treatment modalities for breast cancer include surgical resection, adjuvant radiotherapy, and advanced chemotherapeutic agents such as cisplatin, pacliataxel, carboplatin, bevacizumab, doxorubicin, cyclophosphamide, docetaxel, and epirubicin . Despite advances in treatment strategies, mortality from breast cancer is still high. Combination therapy is gaining increasing attention due to increased antitumor efficacy ,.
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are known to play an opposite role in the regulation of global gene expression via an epigenetic mechanism . HATs catalyze the acetylation of lysine residues in histone tails, facilitating and sustaining gene transcription, while HDACs are responsible for the removal of acetyl groups from the epsilon-amine of lysine residues of histone tails, culminating in prevention of gene transcription. HDAC inhibitors that have the ability to block the activities of HDACs have emerged as effective anticancer agents ,. Suberoyl bis-hydroxamic acid (SBHA) has a similar structure to suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA), two of the mostly studied HDAC inhibitors. SBHA has been found to exert anti-growth effects in several malignancies including breast cancer .
Proteasome inhibitors such as Bortezomib and MG-132 constitute novel anticancer agents . It has been suggested that proteasome inhibitors interfere with the ubiquitin-proteasome pathway that is involved in protein turnover, likely leading to the accumulation of negative regulators of cell growth and survival in cancer cells. Bortezomib has been found to affect the expression of a large number of genes, especially key regulators of apoptosis such as tumor suppressor protein p53 and Bcl-2 family proteins . Preclinical studies have demonstrated the antitumor activity of Bortezomib in breast cancer . MG-132 exposure also induces cytotoxic effects on a variety of cancer cells including breast cancer cells . Combined treatment with HDAC inhibitors and proteasome inhibitors has been reported to enhance anticancer effects compared to each reagent alone ,.
In this study, we aimed to check whether the combination of SBHA with proteasome inhibitors could cause synergistic inhibitory effects on breast cancer cell growth and survival. The molecular pathways involved were also explored.
Cells and reagents
Two human breast cancer cell lines (MCF-7 and MDA-MB-231) and one immortalized breast epithelial cell line (MCF10A) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Fetal bovine serum (FBS), RPMI 1640 medium, DMEM/F-12 medium, and TRIzol reagent were purchased from Invitrogen (Carlsbad, CA, USA), dimethyl sulfoxide (DMSO) from Sigma (St. Louis, MO, USA), SBHA, Bortezomib and MG-132 from Calbiochem (San Diego, CA, USA), Cell Counting Kit-8 (CCK-8) from Dojindo Molecular Technologies (Dojindo, Japan), First Strand cDNA synthesis kit from Fermentas (Burlington, Canada), Annexin-FITC kit from Beckman Coulter (Fullerton, CA, USA), and Apoptotic DNA Ladder Kit (Beyotime, Nantong, China). Antibodies anti-p53, anti-Bcl-2, anti-Bax, and anti-β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-Bak and anti-Bcl-Xs from Calbiochem. Horseradish peroxidase-conjugated goat anti-mouse IgG antibody was obtained from Rockland (Gilbertsville, PA, USA).
Cell culture and treatment
MCF-7 and MDA-MB-231 cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, penicillin (100 units/ml), and streptomycin (100 μg/ml). MCF10A cells were cultured in DMEM/F-12 medium containing 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. They were subcultured every 3-4 days. Twenty-four hours after plating, cells were treated with SBHA (40 μM), Bortezomib (5 nM), and MG-132 (250 nM), alone or in combination, for 72 h and then examined for cell proliferation, apoptosis and gene expression changes. DMSO-treated cells were used as control. To determine the combination index (CI) for combination treatment, MCF-7 and MDA-MB-231 cells were exposed to SBHA plus Bortezomib (a fixed ratio of 8000:1) or SBHA plus MG-132 (a fixed ratio of 160:1) for 72 h and cell viability was assessed using the WST-8 assay. A series of concentrations of SBHA were used, i.e., 10, 20, 40, and 80 μM.
The effect of SBHA on cell proliferation assays was determined with the WST-8 cell proliferation assay kit. Briefly, cells were seeded in 96-well plates at a density of 5 × 103 cells/well and incubated for 24 h. After drug treatment, cells were incubated for further 2 h in the presence of WST-8 reagent. The absorbance (OD) was measured at a wavelength of 450 nm. The CI was calculated according to the classic isobologram equation ; CI values of 1, <1 or >1 indicate additivity, synergism or antagonism.
Colony formation assay
MCF-7 and MDA-MB-231 cells were plated onto 6-well plates and exposed to SBHA (40 μM), Bortezomib (5 nM), and MG-132 (250 nM), alone or in combination, for 72 h. The cells were replated onto 6-well plates at a density of 500 cells per well. After incubation for additional 14 days, cells were washed, fixed in 10% methanol for 15 min, and stained with Giemsa. Colonies consisting of >50 cells were scored. Each experiment was repeated three times.
DNA ladder assay
DNA was extracted from cells after drug treatment with the Apoptotic DNA Ladder Kit according to the manufacture’s instructions. DNA samples were separated by electrophoresis on 2% agarose gel and visualized by ethidium bromide staining.
Apoptosis analysis by annexin-V/PI staining
After drug treatment, cells were harvested through trypsinization, washed, and centrifuged at 1,000 r/min for 5 min. The cell pellet was resuspended in 1 × binding buffer. The cell sample solution (100 μl) was incubated with 1 μl of fluorescein isothiocyanate (FITC)-conjugated annexin V and 5 μl of PI for 15 min at 4°C in the dark. The 1 × binding buffer (400 μl) was added to each sample tube and the samples were analyzed on a FACSCalibur flow cytometer using CellQuest software (BD Biosciences, San Jose, CA, USA).
Reverse transcription-polymerase chain reaction (RT-PCR) analysis
Total RNA was extracted from cells with TRIzol reagent according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesized with the First-Strand cDNA Synthesis Kit for RT-PCR. Amplification of p53 cDNA was achieved with the following primers: forward 5′-CAGTCAGATCCTAGCGTCGAG-3′ and reverse 5′-TGCAAGTCACAGACTTGGCTGT-3′ (product size, 352 bp). For loading control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified in a parallel reaction, with the following primers: forward 5′-GGGAGCCAAAAGGGTCATCATCTC-3′ and reverse 5′-CCATGCCAGTGAGCTTCCCGTTC-3′ (product size, 353 bp). RT-PCR products were separated by electrophoresis on 1.2% agarose gels.
Western blot analysis
After treatment, cells were lysed in lysis buffer (10 mmol/L Tris, pH7.4, 130 mmol/L NaCl, 1% Triton, 10 mmol/L NaF, 10 mmol/L NaPi, 10 mmol/L NaPPi, and 1.5 mmol/L EDTA) supplemented with protease and phosphatase inhibitors. The protein samples were separated on polyacrylamide gels and then transferred to a nitrocellulose membrane. After blocking for 45 min in a Tris buffered solution (TBS) containing 5% fat-free dried milk and 0.5% Tween-20, the membrane was incubated with individual primary antibodies overnight at 4°C. The membrane was washed three times and incubated for 1 h with secondary antibodies at room temperature. The signals were visualized with the enhanced chemiluminescence method. Densitometric analysis of Western blots was performed using the Scion Image Beta 4.02 software (SynGene, Cambridge, UK).
All data were expressed as mean ± standard deviation (SD). Statistical significance was determined using the Student’s t-test or one-way analysis of variance with Tukey's post-test. P values less than 0.05 were considered statistically significant.
Combination of SBHA and proteasome inhibitors inhibits cell viability and colony formation of breast cancer cells
To further explore the effects of combination of SBHA and proteasome inhibitors on breast cancer cell growth, colony formation assay was done. Colonies were counted after 14-day incubation. As illustrated in Figure 1C, treatment with SBHA or proteasome inhibitors alone significantly (P <0.05) decreased the colony formation of MCF-7 cells, compared to DMSO-treated cells. Notably, combined exposure to SBHA and Bortezomib or MG-132 resulted in significantly greater inhibition of colony formation (Figure 1C). Similar findings were obtained in MDA-MB-231 cells treated with SBHA alone or in combination with Bortezomib or MG-132 (Figure 1D).
Combination of SBHA and proteasome inhibitors induces apoptosis in breast cancer cells
Combined exposure of MCF-7 cells to SBHA and proteasome inhibitors upregulates p53 expression
Combined treatment with SBHA and proteasome inhibitors affects the Bcl-2 family proteins
HDAC inhibitors have been extensively studied for their anticancer activities. SBHA is a relatively new HDAC inhibitor and shows growth-suppressive effects in several types of cancers including medullary thyroid cancer  and lung cancer . Zhuang et al.  documented that SBHA induces p53-dependent apoptosis of MCF-7 breast cancer cells. Our present data confirm the anticancer effects of SBHA in breast cancer cells. We found that SBHA treatment significantly inhibited the proliferation and colony formation of MCF-7 cells, compared to DMSO-treated control cells. Similarly, treatment with proteasome inhibitors also caused growth suppressive effects against MCF-7 cells. Most interestingly, combined treatment with SBHA and proteasome inhibitors potentiated the suppression of MCF-7 cell proliferation and colony formation. The CI for combination of SBHA with Bortezomib was 0.60, indicating a synergism. Similar synergistic effects of SBHA and Bortezomib were also observed in MDA-MB-231 cells, with the IC value of 0.57. To the best of our knowledge, this is the first report describing the synergistic effects between HADC inhibitors and proteasome inhibitors in breast cancer. The combination of HDAC inhibitors with Bortezomib has also been found to induce synergistic effects against other types of cancers such as primary effusion lymphoma ,.
Apoptosis is known as an active suicidal response that plays an important role in tumor biology . It is characterized by cellular shrinkage without loss of plasma membrane integrity, formation of apoptotic bodies, and nuclear condensation and fragmentation. Maintenance of plasma membrane integrity during apoptosis prevents the onset of an inflammatory response that contributes to tumor progression . Therefore, specific induction of apoptosis represents a preferred strategy for destroying tumor cells. Notably, our results demonstrated that SBHA exposure caused a significant apoptosis in MCF-7 cells, which is consistent with the previous report . Bortezomib has been documented to induce apoptosis in breast cancer cells ,. Krętowski et al.  reported that Bortezomib treatment evokes a strong effect on apoptosis in breast cancer cells in hypoxic and normoxic conditions. In agreement with these findings, our data confirmed the pro-apoptotic activity of Bortezomib in breast cancer cells. Likewise, MG-132 also showed apoptosis-inducing activity in breast cancer cells. The combination of SBHA with Bortezomib or MG-132 significantly induced apoptosis of MCF-7 and MDA-MB-231 cells compared to each reagent alone. Taken together, these findings suggest that the synergistic anticancer activity of SBHA and proteasome inhibitors in breast cancer cells is, at least partially, mediated through induction of apoptotic death. Although combined treatment with SBHA and Bortezomib or MG-132 caused significant cytotoxicity against breast cancer cells, these combinations did not markedly affect the survival of the non-malignant MCF10A breast epithelial cells. Therefore, the combination of SBHA with Bortezomib or MG-132 may yield specific inhibitory effects on cancer cells.
p53 actively promotes apoptosis and plays a key role in controlling tumor growth . We found that SBHA-treated MCF-7 cells showed a significant elevation in the p53 protein level, but not the p53 mRNA level, suggesting a posttranscriptional regulation. This result is consistent with the previous study that reported an induction of p53 expression in SBHA-treated breast cancer cells . The p53 degradation is largely mediated by the ubiquitin-proteasome pathway . Proteasome inhibition leads to stabilization of p53 . As expected, MCF-7 cells had a significant increase in the p53 protein level after exposure to Bortezomib or MG-132. However, the mRNA abundance of p53 remained unchanged in Bortezomib or MG-132-treated cells. Most interestingly, the p53 protein level was further elevated in MCF-7 cells with combined treatment with SBHA and Bortezomib or MG-132. These findings suggest that induction of p53 may represent an important mechanism for the synergism between SBHA and proteasome inhibitors in breast cancer; however, additional direct evidence is required to confirm the involvement of the p53 pathway.
p53-dependent induction of apoptosis is causally linked to its transcriptional regulation of many target genes. Bax is a downstream target gene of p53 and mediates p53-dependent apoptosis. It has been documented that Bax deficiency impairs p53-induced apoptosis in neurons . The upregulation of Bax is implicated in HDAC inhibitor-induced apoptosis in breast cancer cells . For instance, Wang et al.  reported that sirtinol, a class III HDAC inhibitor, induces apoptotic death in MCF-7 cells through upregulation of Bax. SBHA has also been documented to enhance the expression of Bax in MCF-7 cells, which contributes to p53-dependent apoptosis . In agreement with this study, our data showed that SBHA-treated MCF-7 cells had a significant increase in the Bax protein level. Moreover, the Bcl-xS and Bak proteins were elevated in SBHA-treated cells. When SBHA was combined with Bortezomib or MG-132, the upregulation of Bax, Bcl-xS, and Bak was significantly enhanced. In contrast, the Bcl-2 protein level was deceased upon exposure to SBHA, Bortezomib, and MG-132 alone or in combination. Bax is a pro-apoptotic member of the Bcl-2 family. It undergoes mitochondrial intramembranous homo-oligomerization in response to apoptotic stimuli, which promotes release of cytochrome c from mitochondria, consequently activating the mitochondrial apoptotic pathway . Bcl-xS is localized in the mitochondria and induces apoptosis via activation of Bak . The anti-apoptotic protein Bcl-2 is predominantly localized to mitochondria and can interact with Bax to inhibit its activation . Taken together, our data suggest that the pro-apoptotic activity induced by combined treatment with SBHA and proteasome inhibitors is associated with modulation of the Bcl-2 family members.
SBHA and proteasome inhibitors have shown cytotoxicity in a broad range of cancer types, such as colorectal cancer , prostate cancer , and lung cancer . Combination treatment with HDAC inhibitor TSA and low-dose Bortezomib has been reported to induce synergistic apoptosis in prostate cancer cells . The addition of HDAC inhibitor SAHA to Bortezomib treatment was found to cause synergistic effects against primary effusion lymphoma cells. These studies, combined with our present findings, suggest that apart from breast cancer, the SBHA/proteasome inhibitor combination therapy may induce synergistic cytotoxicity in other types of malignancies.
In conclusion, our data demonstrate that combination of SBHA with proteasome inhibitors enhances anticancer effects on breast cancer cells through promotion of apoptotic death. Induction of p53 and modulation of the Bcl-2 family proteins at least partially account for the synergism between SBHA and proteasome inhibitors. These findings warrant further investigation of the therapeutic potential of combination of SBHA with proteasome inhibitors in breast cancer.
This work was supported by the Scientific Foundation of Shanghai Municipal Health Bureau of China (2012-236).
- Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012, 36: 237-248. 10.1016/j.canep.2012.02.007.View ArticlePubMedGoogle Scholar
- Isakoff SJ: Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010, 16: 53-61. 10.1097/PPO.0b013e3181d24ff7.View ArticlePubMed CentralPubMedGoogle Scholar
- Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009, 27: 5538-5546. 10.1200/JCO.2009.23.3734.View ArticlePubMedGoogle Scholar
- Feng LX, Li M, Liu YJ, Yang SM, Zhang N: Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int J Mol Sci. 2014, 15: 4201-4220. 10.3390/ijms15034201.View ArticlePubMed CentralPubMedGoogle Scholar
- Fukuda H, Sano N, Muto S, Horikoshi M: Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic. 2006, 5: 190-208. 10.1093/bfgp/ell032.View ArticlePubMedGoogle Scholar
- Federico M, Bagella L: Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol. 2011, 2011: 475641-10.1155/2011/475641.View ArticlePubMed CentralPubMedGoogle Scholar
- Meng J, Zhang HH, Zhou CX, Li C, Zhang F, Mei QB: The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol Rep. 2012, 28: 384-388.PubMedGoogle Scholar
- Zhuang ZG, Fei F, Chen Y, Jin W: Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol Sin. 2008, 29: 1459-1466. 10.1111/j.1745-7254.2008.00906.x.View ArticlePubMedGoogle Scholar
- Pellom ST, Shanker A: Development of Proteasome Inhibitors as Therapeutic Drugs. J Clin Cell Immunol. 2012, S5: 5-PubMedGoogle Scholar
- Suh KS, Goy A: Bortezomib in mantle cell lymphoma. Future Oncol. 2008, 4: 149-168. 10.2217/14796622.214.171.124.View ArticlePubMedGoogle Scholar
- Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J: Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 2006, 5: 665-675. 10.1158/1535-7163.MCT-05-0147.View ArticlePubMedGoogle Scholar
- Ju D, Wang X, Xie Y: Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells. Int J Mol Med. 2009, 23: 205-209.PubMed CentralPubMedGoogle Scholar
- Sato A, Asano T, Ito K, Asano T: Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. J Urol. 2012, 188: 2410-2418. 10.1016/j.juro.2012.07.108.View ArticlePubMedGoogle Scholar
- Komatsu S, Moriya S, Che XF, Yokoyama T, Kohno N, Miyazawa K: Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochem Biophys Res Commun. 2013, 437: 41-47. 10.1016/j.bbrc.2013.06.032.View ArticlePubMedGoogle Scholar
- Zhao L, Wientjes MG, Au JL: Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004, 10: 7994-8004. 10.1158/1078-0432.CCR-04-1087.View ArticlePubMedGoogle Scholar
- Ning L, Jaskula-Sztul R, Kunnimalaiyaan M, Chen H: Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol. 2008, 15: 2600-2605. 10.1245/s10434-008-0006-z.View ArticlePubMed CentralPubMedGoogle Scholar
- You BR, Park WH: Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. Mol Cell Biochem. 2010, 344: 203-210. 10.1007/s11010-010-0543-1.View ArticlePubMedGoogle Scholar
- Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS, Ramos JC: Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. J Clin Invest. 2013, 123: 2616-2628. 10.1172/JCI64503.View ArticlePubMed CentralPubMedGoogle Scholar
- Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J: HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PLoS One. 2012, 7: e52576-10.1371/journal.pone.0052576.View ArticlePubMed CentralPubMedGoogle Scholar
- Cotter TG: Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009, 9: 501-507. 10.1038/nrc2663.View ArticlePubMedGoogle Scholar
- Beckta JM, Ahmad SF, Yang H, Valerie K: Revisiting p53 for cancer-specific chemo- and radiotherapy: Ten years after. Cell Cycle. 2014, 13: 710-713. 10.4161/cc.28108.View ArticlePubMed CentralPubMedGoogle Scholar
- Yerlikaya A, Okur E, Ulukaya E: The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol. 2012, 33: 1385-1392. 10.1007/s13277-012-0386-3.View ArticlePubMedGoogle Scholar
- Krętowski R, Borzym-Kluczyk M, Cechowska-Pasko M: Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231. Mol Cell Biochem. 2014, 389: 177-185. 10.1007/s11010-013-1939-5.View ArticlePubMed CentralPubMedGoogle Scholar
- Devine T, Dai MS: Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des. 2013, 19: 3248-3262. 10.2174/1381612811319180009.View ArticlePubMed CentralPubMedGoogle Scholar
- Miyamoto Y, Nakagawa S, Wada-Hiraike O, Seiki T, Tanikawa M, Hiraike H, Sone K, Nagasaka K, Oda K, Kawana K, Nakagawa K, Fujii T, Yano T, Kozuma S, Taketani Y: Sequential effects of the proteasome inhibitor bortezomib and chemotherapeuticagents in uterine cervical cancer cell lines. Oncol Rep. 2013, 29: 51-57.PubMedGoogle Scholar
- Cregan SP, MacLaurin JG, Craig CG, Robertson GS, Nicholson DW, Park DS, Slack RS: Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci. 1999, 19: 7860-7869.PubMedGoogle Scholar
- Wang J, Kim TH, Ahn MY, Lee J, Jung JH, Choi WS, Lee BM, Yoon KS, Yoon S, Kim HS: Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol. 2012, 41: 1101-1109.PubMedGoogle Scholar
- Danial NN: BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007, 13: 7254-7263. 10.1158/1078-0432.CCR-07-1598.View ArticlePubMedGoogle Scholar
- Lindenboim L, Kringel S, Braun T, Borner C, Stein R: Bak but not Bax is essential for Bcl-xS-induced apoptosis. Cell Death Differ. 2005, 12: 713-723. 10.1038/sj.cdd.4401638.View ArticlePubMedGoogle Scholar
- Chen S, Dai Y, Pei XY, Grant S: Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009, 29: 6149-6169. 10.1128/MCB.01481-08.View ArticlePubMed CentralPubMedGoogle Scholar
- Flis S, Gnyszka A, Spławiński J: HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun. 2009, 387: 336-341. 10.1016/j.bbrc.2009.07.017.View ArticlePubMedGoogle Scholar
- Kiliccioglu I, Konac E, Varol N, Gurocak S, Yucel Bilen C: Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines. Genet Mol Res. 2014, 13: 3721-3731. 10.4238/2014.May.9.17.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.